Serum TNF-α, IL-10 and IL-2 in schizophrenic patients before and after treatment with risperidone and clozapine.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Iranian journal of immunology : IJI

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 25265997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia.

  2013cited by this paper
• Increased interleukin-6 and tumor necrosis factor alpha in first episode schizophrenia patients versus healthy controls.

  2012cited by this paper
• Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: Voxel-based-morphometry (VBM) study

  2012cited by this paper
• Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance.

  2011cited by this paper
• Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls

  2011cited by this paper
• Expression of anti-cardiolipin antibodies and inflammatory associated factors in patients with schizophrenia.

  2011cited by this paper
• Increased interleukin-6 level in Taiwanese schizophrenic patients.

  2011cited by this paper
• Comprar Kaplan and Sadocks Pocket Handbook of Clinical Psychiatry, 5/e | Virginia A. Sadock | 9781605472645 | Lippincott Williams & Wilkins

  2010cited by this paper
• The blood brain barrier and the role of ratiometric molecular analysis in schizophrenia.

  2010cited by this paper
• Cytokine Changes and Tryptophan Metabolites in Medication-Naïve and Medication-Free Schizophrenic Patients

  2009cited by this paper
• Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients.

  2009cited by this paper
• Die Bedeutung des TNF-α-Systems für Erkrankungen des Gehirns

  2009cited by this paper
• Increased tumor necrosis factor-alpha concentrations with interleukin-4 concentrations in exacerbations of schizophrenia.

  2008cited by this paper
• Monocytic, Th1 and Th2 Cytokine Alterations in the Pathophysiology of Schizophrenia

  2007cited by this paper
• Dopamine D3 receptor and schizophrenia: a widened scope for the immune hypothesis.

  2006cited by this paper
• Role of IL-6 in the neural stem cell differentiation

  2005cited by this paper
• Cytokines and sleep.

  2005cited by this paper
• Interleukin-2 levels in chronic schizophrenia patients.

  2004cited by this paper
• The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis.

  2003cited by this paper
• Neuroendocrine immune interactions in health and disease.

  2003cited by this paper
• TH1/TH2 CYTOKINES IN THE CENTRAL NERVOUS SYSTEM

  2002cited by this paper
• Cytokines and Cognition—The Case for A Head‐to‐Toe Inflammatory Paradigm

  2002cited by this paper
• Serum IL-1 b , sIL-2 R , IL-6 , IL-8 and TNF-a in schizophrenic patients , relation with symptomatology and responsiveness to risperidone treatment

  2001cited by this paper
• Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients.

  2001cited by this paper
• Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients.

  2001cited by this paper
• Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action.

  1999cited by this paper
• Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.

  1999cited by this paper
• Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment.

  1997cited by this paper
• Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2.

  1997cited by this paper
• Clozapin, Zytokine, Fieber und Schlaf

  1996cited by this paper
• Effects of clozapine on plasma cytokine and soluble cytokine receptor levels.

  1996cited by this paper
• Enhancement of intracellular replication of Toxoplasma gondii by IL-6. Interactions with IFN-gamma and TNF-alpha.

  1994cited by this paper
• Expression of cytokine receptors in cultured neuronal and glial cells.

  1993cited by this paper
• Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta.

  1992cited by this paper
• Immune cytokines and regulation of body temperature, food intake and cellular immunity.

  1991cited by this paper
• Pocket Handbook of Clinical Psychiatry

  1990cited by this paper

• A Literature Review and Preliminary Study on Proteomic Research Associated With the Therapeutic Mechanism and Efficacy of Electroconvulsive Therapy in Schizophrenia Patients

  2025cites this paper
• Deterioration of COVID-19 vaccine efficacy by antipsychotic medications in schizophrenia patients

  2025cites this paper
• The role of neuroinflammation in schizophrenia: Focus on Th17 cells functions.

  2025cites this paper
• Effect of Electroconvulsive Therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and Soluble IL-2 Receptor in Treatment-Resistant Schizophrenia (TRS) Patients—A Preliminary Study

  2025cites this paper
• Changes in inflammatory parameters and antioxidants and their impact on clinical symptoms, including cognitive functions, in patients with schizophrenia - scoping review

  2024cites this paper
• The effect of clozapine on immune-related biomarkers in schizophrenia patients.

  2024cites this paper
• Current Strategies and Future Directions of Wearable Biosensors for Measuring Stress Biochemical Markers for Neuropsychiatric Applications

  2024cites this paper
• Changes in IL-6, IL-12, IL-5, IL-10 and TGF-β1 Concentration in Patients with Treatment-Resistant Schizophrenia (TRS) Following Electroconvulsive Therapy (ECT)—A Pilot Study

  2024cites this paper
• Effects of 6-week olanzapine treatment on serum IL-2, IL-4, IL-8, IL-10, and TNF-α levels in drug-naive individuals with first-episode schizophrenia

  2024cites this paper
• Immunoinflammatory and oxidative alterations in subjects with schizophrenia under clozapine: A meta-analysis.

  2023cites this paper
• A systematic review of clozapine‐associated inflammation and related monitoring

  2023cites this paper
• The Effectiveness of Meloxicam Adjuvant Therapy to Improve Cognitive Function of Schizophrenic Patients

  2023cites this paper
• Is there any association between cognitive deficits and immune markers in Acute and Transient psychotic disorders? A pilot study.

  2023cites this paper
• Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: A systematic review and meta-analysis.

  2023cites this paper
• Serum Levels and in vitro CX3CL1 (Fractalkine), CXCL8, and IL-10 Synthesis in Phytohemaglutinin-Stimulated and Non-stimulated Peripheral Blood Mononuclear Cells in Subjects With Schizophrenia

  2022cites this paper
• Comparative effects of clozapine and risperidone monotherapy on levels of immunoglobulins in patients with schizophrenia – A 12 weeks' longitudinal study

  2022cites this paper
• Pharmacological Targets and Mechanisms of Action of Antipsychotic Substances in the Context of the Neurochemical Theory of the Pathogenesis of Schizophrenia

  2022cites this paper
• Immune‐mediated inflammatory markers in acute and transient psychotic disorders—comparison with schizophrenia: An exploratory comparative study

  2022cites this paper
• Cytokine Imbalance in Schizophrenia. From Research to Clinic: Potential Implications for Treatment

  2021cites this paper
• Serum Interleukin-2 (IL-2) Levels in Untreated and Treated in Batak Tribe Patients with Schizophrenia

  2021cites this paper
• Modeling Schizophrenia with Glioblastoma Cells: In Vitro Analysis of Risperidone Treatment on Glial Spheroids

  2021cites this paper
• Role of Tumor Necrosis Factor-Alpha in Schizophrenia and Cognitive Impairment

  2021cites this paper
• Differences between Tumor Necrosis Factor-Alpha Levels and Interleukin-2 Levels in people with schizophrenia who get risperidone drugs in the acute phase of treatment in the Prof. DR. M. Ildrem Psychiatric Hospital, Medan

  2021cites this paper
• Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients

  2021cites this paper
• Cytokine Level and Symptoms of Schizophrenia

  2021cites this paper
• Brain stimulation effects on serum BDNF, VEGF, and TNFα in treatment‐resistant psychiatric disorders

  2021cites this paper
• Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

  2020cites this paper
• A Rapid Method for Analysis of cDNA Synthesis Using Ion-Pair Reversed-Phase High Performance Liquid Chromatography

  2020cites this paper
• Evaluation of IFN-γ and T-bet Expression Levels as Possible Molecular Markers of Schizophrenia

  2020cites this paper
• Immune Factor, TNFα, Disrupts Human Brain Organoid Development Similar to Schizophrenia—Schizophrenia Increases Developmental Vulnerability to TNFα

  2020cites this paper
• Evaluating the Hypothesis That Schizophrenia Is an Inflammatory Disorder.

  2020cites this paper
• Cytokine Alterations in Schizophrenia: An Updated Review

  2019cites this paper
• Risk Factors and Outcome Predicating Biomarker of Neurodegenerative Diseases

  2019cites this paper
• Inflammatory biomarkers in schizophrenia: Implications for heterogeneity and neurobiology

  2019cites this paper
• Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

  2018cites this paper
• Study of Novel Autoantibodies in Schizophrenia

  2018cites this paper
• A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis

  2018cites this paper
• Decreased peripheral TNF alpha (TNF-α) mRNA expression in patients with treatment-resistant schizophrenia.

  2018cites this paper
• Kinetics of Cytokine Levels during Antipsychotic Treatment in Schizophrenia: A Meta-Analysis

  2018cites this paper
• Pretreatment With Risperidone Ameliorates Systemic LPS-Induced Oxidative Stress in the Cortex and Hippocampus

  2018cites this paper
• Comparison of Serum Levels of Tumor Necrosis Factor Alpha (TNF-α) in Batak Male Schizophrenic Patients Versus Healthy Controls

  2018cites this paper
• Tumor necrosis factor-α and -β genetic polymorphisms as a risk factor in Saudi patients with schizophrenia

  2017cites this paper
• Serum Levels of Tumor Necrosis Factor Alpha in Chronic Schizophrenic Versus Healthy Control and Correlation with Severity of Illness

  2017cites this paper
• Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions

  2017cites this paper
• Inhibitory effect of Dendrobium officinale polysaccharide on human gastric cancer cell xenografts in nude mice

  2017cites this paper
• Blood–brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders

  2016cites this paper
• The Immunology of Behavior ‖ Towards an Immunophenotype of Schizophrenia : Progress , Potential Mechanisms , and Future Directions Running Title : Schizophrenia Immunophenotype

  2016cites this paper
• Metabolic adverse effects in clozapine-treated patients with schizophrenia : Cytokine and adipokine alterations, neuropeptide Y, and genetic associations

  2016cites this paper
• Elevated Serum Interleukin-23 and Interleukin-6 Levels in Schizophrenic Patients Compared to Those in Healthy Controls

  2016cites this paper
• Altered IL-2 and IL-10 serum levels in schizophrenic patients

  2015cites this paper
• Detection and significance of serum interleukin-6 , tumor necrosis factor-毩 and interleukin-1 毬 in first-episode schizophrenia patients

  2015cites this paper
• TNF-related weak inducer of apoptosis (TWEAK) levels in schizophrenia.

  2015cites this paper